Literature DB >> 23452774

[Inborn errors of metabolism in adult neurology].

F Sedel1.   

Abstract

Inborn errors of metabolism (IEM) are caused by mutations in genes coding for enzymes and other proteins involved in cell metabolism. Many IEM can be treated effectively. Although IEM have usually been considered pediatric diseases, they can present at any age, mostly with neurological and psychiatric symptoms, and therefore constitute an integral subspeciality of neurology. However, although they are increasingly being recognized, IEM remain rare, and the care for patients should be optimized in specialized reference centers. Since the number of different diseases is very large, the diagnostic approach needs to be rigorous, starting at the clinics and calling upon the additional help of neuroradiology, biochemistry and molecular biology. In practice, it is important for the neurologist to recognize: (1) when to start suspecting an IEM; and (2) how to correlate a given clinical presentation with one of the five major groups of diseases affecting the nervous system. These five groups may be classified as: (a) energy metabolism disorders such as respiratory chain disorders, pyruvate dehydrogenase deficiency, GLUT1 deficiency, fatty-acid β-oxidation defects, and disorders involving key cofactors such as electron transfer flavoprotein, thiamine, biotin, riboflavin, vitamin E and coenzyme Q10; (b) intoxication syndromes such as porphyrias, urea-cycle defects, homocystinurias, organic acidurias and amino acidopathies; (c) lipid-storage disorders such as lysosomal storage disorders (Krabbe disease, metachromatic leukodystrophy, Niemann - Pick disease type C, Fabry disease and Gaucher's disease), peroxisomal disorders (adrenomyeloneuropathy, Refsum disease, disorders of pristanic acid metabolism, peroxisome biogenesis disorders), Tangier disease and cerebrotendinous xanthomatosis; (d) metal-storage diseases such as iron, copper and manganese metabolic disorders; and (e) neurotransmitter metabolism defects, including defects of serotonin, dopamine and glycine metabolism.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23452774     DOI: 10.1016/S0035-3787(13)70062-6

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  7 in total

1.  Inborn errors of metabolism: challenges and management.

Authors:  Subir Kumar Das
Journal:  Indian J Clin Biochem       Date:  2013-10

Review 2.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

3.  Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo.

Authors:  Chun-Te Chen; Yi-Chun Chen; Hirohito Yamaguchi; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

Review 4.  Psychiatric manifestations in cerebrotendinous xanthomatosis.

Authors:  M J Fraidakis
Journal:  Transl Psychiatry       Date:  2013-09-03       Impact factor: 6.222

5.  Clinical characteristics of adult patients with inborn errors of metabolism in Spain: A review of 500 cases from university hospitals.

Authors:  J Pérez-López; L Ceberio-Hualde; J S García-Morillo; J M Grau-Junyent; A Hermida Ameijeiras; M López-Rodríguez; J C Milisenda; M Moltó Abad; M Morales-Conejo; J J Nava Mateos
Journal:  Mol Genet Metab Rep       Date:  2017-02-03

Review 6.  An overview of inborn errors of metabolism affecting the brain: from neurodevelopment to neurodegenerative disorders.

Authors:  Jean-Marie Saudubray; Angela Garcia-Cazorla
Journal:  Dialogues Clin Neurosci       Date:  2018-12       Impact factor: 5.986

7.  Clouds over IMD? Perspectives for inherited metabolic diseases in adults from a retrospective cohort study in two Swiss adult metabolic clinics.

Authors:  Karim Gariani; Marina Nascimento; Andrea Superti-Furga; Christel Tran
Journal:  Orphanet J Rare Dis       Date:  2020-08-18       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.